Mouse model for inflammasome-mediated rheumatoid arthritis research
Innovative mouse model mimicking rheumatoid arthritis through inflammasome activation provides a platform for validating new therapeutic strategies targeting inflammasome and necroptosis pathways.
Overview
Our unique mouse model of rheumatoid arthritis (RA) offers a novel approach to study the disease's pathogenesis and test potential treatments. Unlike traditional models dependent on TNF, this model highlights the role of myeloid cell necroptosis and IL-1b cytokine release through inflammasome activation. This breakthrough allows for the exploration of inflammasome and necroptosis-based therapeutic strategies, offering new avenues for RA treatment.
Technical specifications
- Unique model: Based on myeloid cell necroptosis and inflammasome activation rather than TNF-dependence.
- Cytokine focus: Centralizes the role of IL-1b in RA pathogenesis.
- Therapeutic validation: Provides a platform to test inflammasome and necroptosis-targeting therapies.
- Future developments: Includes creating a transgenic mouse line with cell type-specific expression of a ZnF7 peptide to inhibit macrophage necroptosis and developing a ZnF7 peptide delivery system for potential pharmacological use.
Technology readiness level
This technology is at TRL 4, indicating that it has been validated in the lab and is ready for experimental applications in specialized settings to further explore its therapeutic potential.
About VIB (Flanders Institute for Biotechnology)
VIB (Flanders Institute for Biotechnology) is a premier life sciences research institute based in Belgium. It focuses on translating excellent fundamental research into societal and economic impact through state-of-the-art technology, specialized core facilities, and a robust technology transfer and spin-off ecosystem.
delivered to your inbox.